The role of animal models in influenza vaccine research

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 223-272

  Luke, Catherine J ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE; IMMUNOGLOBULIN A; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY TITER; ARTICLE; CAT; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL MODEL; FERRET; GUINEA PIG; HAMSTER; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N1; INFLUENZA VIRUS A H9N2; MACACA; MEDICAL DECISION MAKING; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIMATE; PRIORITY JOURNAL; RAT; RODENT; SEASONAL INFLUENZA; STRAIN DIFFERENCE; TOXICITY TESTING; VIRUS STRAIN; WEIGHT REDUCTION;

EID: 79960059140     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0279-2_10     Document Type: Article

References (185)

1. Palese P, Shaw ML (2007) Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1647-1689
2. Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxoviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (eds) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1691-1740
3. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79:2814-2822
4. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179
5. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51:407-421
6. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J et al (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396
7. Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 63:4603-4608
8. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V et al (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201
9. Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpanth S, Wattanodorn S, Theambooniers A, Tantilertcharoen R et al (2004) Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 10:2189-2191
10. Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, Osterhaus A (2004) Avian H5N1 influenza in cats. Science 306:241
11. Couch RB, Kasel JA (1983) Immunity to influenza in man. Annu Rev Microbiol 37:529-549
12. Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 70:767-777
13. Treanor J, Wright PF (2003) Immune correlates of protection against influenza in the human challenge model. In: Brown F, Haaheim LR, Schild GC (eds) Laboratory correlates of immunity to influenza - a reassessment. Karger, Basel, pp 97-104
14. Clements ML, Murphy BR (1986) Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23:66-72
15. Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN (2004) Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 190:11-19
16. Murphy BR, Coelingh K (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15:295-323
17. Smith W, Andrewes CH, Laidlaw PP (1933) A virus obtained from influenza patients. Lancet 222:66-68
18. Andrewes CH, Laidlaw PP, Smith W (1934) The susceptibility of mice to the viruses of human and swine influenza. Lancet 224:859-862
19. Brown EG (1990) Increased virulence of a mouse-adapted variant of Influenza A/FM/1/47 virus is controlled by mutations in genome segments 4, 5, 7 and 8. J Virol 64:4523-4533
20. Brown EG, Liu H, Chang Kit L, Baird S, Nesrallah M (2001) Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes. Proc Natl Acad Sci USA 98:6883-6888
21. Smeenk CA, Brown EG (1994) The Influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol 68:530-534
22. Smeenk CA, Wright KE, Burns BF, Thaker AJ, Brown EG (1996) Mutations in the hemagglutinin and matrix genes of a virulent influenza virus variant, A/FM/1/47-MA, control different stages in pathogenesis. Virus Res 44:79-95
23. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martinez-Sobrido L, Solorzano A, Garcia-Sastre A, Haller O, Kochs G (2007) Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx resistance gene. Proc Natl Acad Sci USA 104:6806-6811
24. Epstein SL, Lo CY, Misplon JA, Lawson CM, Hendrickson BA, Max EE, Subbarao K (1997) Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, ß2-microglobulin-deficient, and J chain-deficient mice. J Immunol 158:1222-1230
25. Tumpey TM, Szretter KJ, Van Hoeven N, Katz JM, Kochs G, Haller O, Garcia-Sastre A, Staeheli P (2007) The Mx1 gene protects mice against pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol 81:10818-10821
26. Virelizier J (1975) Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 115:434-439
27. Ramphal R, Cogliano RC, Shands JWJ, Small PAJ (1979) Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 25:992-997
28. Takiguchi K, Sugawara K, Hongo S, Nishimura H, Kitame F, Nakamura K (1992) Protective effect of serum antibody on respiratory infection of influenza C virus in rats. Arch Virol 122:1-11
29. Prince GA, Horswood RL, Chanock RM (1985) Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55:517-520
30. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B (2004) Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78:3572-3577
31. Iida T, Bang FB (1963) Infection of the upper respiratory tract of mice with influenza virus. Am J Hyg 77:169-176
32. Yetter RA, Lehrer S, Ramphal R, Small PAJ (1980) Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29:654-662
33. Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O (1988) Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 8:4518-4523
34. Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C (1986) Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44:147-158
35. Abou-Donia H, Jennings R, Potter CW (1980) Growth of influenza A viruses in hamsters. Arch Virol 65:99-107
36. Heath AW, Addison C, Ali M, Teale D, Potter CW (1983) In vivo and in vitro hamster models in the assessment of virulence of recombinant influenza viruses. Antiviral Res 3:241-252
37. Murphy BR, Wood FT, Massicot JG, Chanock RM (1978) Temperature-sensitive mutants of influenza virus. XVI. Transfer of the two ts lesions present in the Udorn/72-ts-1A2 donor virus to the Victoria/3/75 wild-type virus. Virology 88:244-251
38. Subbarao EK, Kawaoka Y, Murphy BR (1993) Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol 67:7223-7228
39. Phair JP, Kauffman CA, Jennings R, Potter CW (1979) Influenza virus infection of the guinea pig: immune response and resistance. Med Microbiol Immunol 165:241-254
40. Azoulay-Dupuis E, Lambre CR, Soler P, Moreau J, Thibon M (1984) Lung alterations in guinea-pigs infected with influenza virus. J Comp Path 94:273-283
41. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P (2006) The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci USA 103:9988-9992
42. Ali M, Maassab HF, Jennings R, Potter CW (1982) Infant rat model of attenuation for recombinant influenza viruses prepared from cold-adapted attenuated A/Ann/Arbor/6/60. Infect Immun 38:610-619
43. Mahmud MIA, Jennings R, Potter CW (1979) The infant rat as a model for assessment of the attenuation of human influenza viruses. J Med Microbiol 12:43-54
44. Teh C, Jennings R, Potter CW (1980) Influenza virus infection of newborn rats: virulence of recombinant strains prepared from influenza virus strain A/Okuda/57. J Med Microbiol 13:297-306
45. Niewiesk S, Prince G (2002) Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 36:357-372
46. Sadowski W, Wilczynski J, Semkow R, Tulimowska M, Krus S, Kantoch M (1987) The cotton rat (Sigmodon hispidus) as an experimental model for studying viruses in respiratory tract infections. II. Influenza viruses types A and B. Med Dosw Mikrobiol 39:43-55
47. Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA (2005) The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 86:2823-2830
48. Burnet FM (1941) Influenza virus "A" infections of cynomolgus monkeys. Aust J Exp Biol Med Sci 19:281-290
49. Saslaw S, Wilson HE, Doan CA, Woolpert OC, Schwab JL (1946) Reactions of monkeys to experimentally induced influenza virus A infection. An analysis of the relative roles of humoral and cellular immunity under conditions of optimal or deficient nutrition. J Exp Med 84:113-125
50. Rimmelzwaan GF, Baars M, van Beek R, Van Amerongen G, Lovgren-Bengtsson K, Claas ECJ, Osterhaus ADME (1997) Induction of protective immunty against influenza virus in a macaque model: comparison of conventional and ISCOM vaccines. J Gen Virol 78:757-765
51. Baskin CR, Garcia-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villan E, Katze MG (2004) Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol 78:10420-10432
52. Murphy BR, Lewis Sly D, Hosier NT, London WT, Chanock RM (1980) Evaluation of three strains of influenza A virus in humans and in owl, cebus and squirrel monkeys. Infect Immun 28:688-691
53. Murphy BR, Hinshaw VS, Lewis Sly D, London WT, Hosier NT, Wood FT, Webster RG, Chanock RM (1982) Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun 37:1119-1126
54. Snyder MH, Clements ML, Herrington D, London WT, Tierney EL, Murphy BR (1986) Comparison by studies in squirrel monkeys, chimpanzees, and adult humans of avian-human influenza A virus reassortants derived from different avian influenza virus donors. J Clin Microbiol 24:467-469
55. Grizzard MB, London WT, Sly DL, Murphy BR, James WD, Parnell WP, Chanock RM (1978) Experimental production of respiratory tract disease in cebus monkeys after intratracheal or intranasal infection with influenza A/Victoria/3/75 or influenza A/New Jersey/76 virus. Infect Immun 21:201-205
56. Murphy BR, Hall SL, Crowe J, Collins PL, Subbarao EK, Connors M, London WT, Chanock RM (1992) The use of chimpanzees in respiratory virus research. In: Erwin J, Landon JC (eds) Chimpanzee conservation and public health: environments for the future. Diagnon/Bioqual, Rockville, MD
57. Snyder MH, London WT, Tierney EL, Maassab HF, Murphy BR (1986) Restricted replication of a cold-adapted reassortant influenza A virus in the lower respiratory tract of chimpanzees. J Infect Dis 154:370-371
58. WHO (2005) WHO guidelines on nonclinical evaluation of vaccines. World Health Organization, Geneva. Annex 1
59. Sugg JY (1949) An Influenza virus pneumonia of mice that is nontransferable by serial passage. J Bacteriol 57:399-403
60. Henle W, Henle G (1946) Studies on the toxicity of influenza viruses. II. The effect of intraabdominal and intravenous injection of influenza viruses. J Exp Med 84:639-661
61. Jin H, Manetz S, Leininger J, Luke C, Subbarao K, Murphy B, Kemble G, Coelingh KL (2007) Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 25:8664-8672
62. Betts RF, Douglas GRJ, Maassab HF, DeBorde DC, Clements ML, Murphy BR (1988) Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold-adapted vaccine recombinant in which vaccine-associated illness occurred in normal volunteers. J Med Virol 26:175-183
63. Murphy BR, Holley HP, Berquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM (1979) Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun 23:253-259
64. Okuno Y, Nakamura K, Yamamura T, Takahashi M, Toyoshima K, Kunita N, Sugai T, Fujita T (1960) Studies on attenuation of influenza virus. Proc Jpn Acad 36:299-303
65. Center for Biologics Evaluation and Research (CBER) 21 CFR PART 610 General biological products standards, Rockville, MD, USA, (Food and Drug Administration)
66. Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G et al (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3:e360
67. WHO (2003) Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment. World Health Organization, Geneva
68. Gonin P, Gaillard C (2002) Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 11:S98-S108
69. Leamy VL, Martin T, Mahajan R, Vilalta A, Rusalov D, Hartikka J, Bozoukova V, Hall KD, Morrow J, Rolland AP et al (2006) Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. Hum Vaccin 2:113-118
70. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, Harper LB, Schock HB, Zhang H, Faris JE et al (2002) Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol (Basel) 104:33-43
71. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Griffiths TG, Niu Z, Denisova L, Follmer TT et al (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43:273-281
72. Winegar RA, Monforte JA, Suing KD, O'Loughlin KG, Rudd CJ, Macgregor JT (1996) Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. Hum Gene Ther 7:2185-2194
73. Maassab HF, Kendal AP, Abrams GD, Monto AS (1982) Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 146:780-790
74. Murphy BR, Sly DL, Tierney EL, Hosier NT, Massicot JG, London WT, Chanock RM, Webster RG, Hinshaw VS (1982) Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science 218:1330-1332
75. EMEA (2003) Points to consider on the development of live attenuated Influenza vaccines, European Agency for the Evaluation of Medicinal Products (EMEA), London, CPMP/BWP/2289/01
76. Rubin SA, Liu D, Pletnikov M, McCullers JA, Ye Z, Levandowski RA, Johannessen J, Carbone KM (2004) Wild-type and attenuated influenza virus infection of the neonatal rat brain. J Neurovirol 10:305-314
77. Smith W, Andrewes CH, Laidlaw PP (1935) Influenza: experiments on the immunization of ferrets and mice. Brit J Exp Pathol 16:291-302
78. Potter CW, Oxford JS, Shore SL, McLaren C, Stuart-Harris CH (1972) Immunity to influenza in ferrets. I. Response to live and killed virus. Brit J Exp Pathol 53:153-167
79. Potter CW, Shore SL, McLaren C, Stuart-Harris CH (1972) Immunity to influenza in ferrets. 2. Influence of adjuvants on immunization. Brit J Exp Pathol 53:168-179
80. Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL (2001) Heterosubtypic immunity to Influenza A virus in mice lacking IgA, all Ig, NKT cells or gd T cells. J Immunol 166:7437-7445
81. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160:322-327
82. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J (2001) Heterosubtypic immunity to Influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183:368-376
83. Nguyen HH, Zemlin M, Ivanov II, Andrasi J, Zemlin C, Vu HL, Schelonka R, Schroeder HWJ, Mestecky J (2007) Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J Virol 81:9331-9338
84. McLaren C, Potter CW (1974) Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines. J Hyg 72:91-100
85. McLaren C, Potter CW, Jennings R (1974) Immunity to influenza in ferrets. X. Intranasal immunization of ferrets with inactivated influenza A virus vaccines. Infect Immun 9:985-990
86. Yetter RA, Barber WH, Small PAJ (1980) Heterotypic immunity to influenza in ferrets. Infect Immun 29:650-653
87. Straight TM, Ottolini MG, Prince GA, Eichelberger MC (2006) Evidence of a cross-protective immune response to influenza A in the cotton rat model. Vaccine 24:6264-6271
88. Epstein SL (2006) Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957. J Infect Dis 193:49-53
89. Steinhoff MC, Fries LF, Karron RA, Clements ML, Murphy BR (1993) Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 31:836-838
90. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8:796-801
91. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K et al (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19:3681-3691
92. Ulmer J, Donnelly J, Parker S, Rhodes G, Felgner P, Dwarki V, Gromkowski S, Deck R, DeWitt C, Friedman A et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749
93. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13:1399-1402
94. Fan J, Liang X, Horton M, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM et al (2004) Preclinical study of influenza virus A M2 peptide conjugate in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003
95. DeFilette M, Friers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597-6601
96. DeFilette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Friers W (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149-161
97. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Friers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163
98. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ (2007) Crossreactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59
99. Murphy BR, Kasel JA, Chanock RM (1972) Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286:1329-1332
100. Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, Cooley AJ, Kawaoka Y (1999) Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 73:3184-3189
101. Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K (2000) Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol 74:10807-10810
102. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73:5903-5911
103. Dybing JK, Schultz-Cherry S, Swayne DE, Suarez DL, Perdue ML (2000) Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J Virol 74:1443-1450
104. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P et al (2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79:11788-11800
105. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943
106. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21:1687-1693
107. Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362:1959-1966
108. Subbarao K, Luke CJ (2007) H5N1 viruses and vaccines. PLoS Pathog 3:e40
109. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664
110. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351
111. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z et al (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368:991-997
112. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24:6859-6866
113. Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Tong T, Zhong G et al (2009) Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5:e1000409
114. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin AR, Stephenson I, Szretter KJ, Cox NJ, Rudenko LG, Klimov A et al (2006) Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593
115. Belser JA, Lu X, Maines TR, Smith C, Li Y, Donis RO, Katz JM, Tumpey TM (2007) Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol 81:11139-11147
116. Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K (2007) Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol 81:10558-10566
117. de Wit E, Munster V, Spronken MIJ, Bestebroer TM, Baas C, Beyer WEP, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM (2005) Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 79:12401-12407
118. Munster VJ, de Wit E, van Riel D, Beyer WEP, Rimmelzwaan GF, Osterhaus ADME, Kuiken T, Fouchier RAM (2007) The molecular basis of the pathogenicity of the Dutch highly pathogenic human influenza A H7N7 viruses. J Infect Dis 196:258-265
119. Rigoni M, Shinya K, Toffan A, Milani A, Bettini F, Kawaoka Y, Cattoli G, Capua I (2007) Pneumo- and neurotropism of avian origin Italian highly pathogenic avian influenza H7N1 isolates in experimentally infected mice. Virology 364:28-35
120. Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y (2008) Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 26:1742-1750
121. Pappas C, Matsuoka Y, Swayne DE, Donis RO (2007) Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol 14:1425-1432
122. Cox RJ, Major D, Hauge S, Madhun AS, Brokstad KA, Kuhne M, Smith J, Vogel FR, Zambon M, Haaheim LR et al (2009) A cell-based H7N1 split influenza virion vaccineconfers protection in mouse and ferret challenge models. Influenza Other Respi Viruses 3:107-117
123. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Hoschler K, Saville M, Vogel FR, Barclay W et al (2009) A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27:1889-1897
124. Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K (2008) A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378:123-132
125. Guo Y, Li J, Cheng X (1999) Discovery of men infected by avian influenza A (H9N2) virus. Chinese. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13:105-108
126. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PLS, Lai RWM, Orr WK, Shortridge KF (1999) Human infection with influenza H9N2. Lancet 354:916-917
127. Guan Y, Shortridge KF, Krauss S, Webster RG (1999) Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci USA 96:9363-9367
128. Guo YJ, Krauss S, Senne DA, Mo IP, Lo KS, Xiong XP, Norwood M, Shortridge KF, Webster RG, Guan Y (2000) Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology 267:279-288
129. Shortridge KF (1999) Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: abridged chronology and virus isolation. Vaccine 17(Suppl 1):S26-S29
130. Xu KM, Li KS, Smith GJ, Li JW, Tai H, Zhang JX, Webster RG, Peiris JS, Chen H, Guan Y (2007) Evolution and molecular epidemiology of H9N2 influenza A viruses from quail in southern China, 2000-2005. J Virol 81:2635-2645
131. Xu KM, Smith GJ, Bahl J, Duan L, Tai H, Vijaykrishna D, Wang J, Zhang JX, Li KS, Fan XH et al (2007) The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol 81:10389-10441
132. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG (2001) Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 45:1216-1224
133. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG (2000) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101-115
134. Lu X, Renshaw M, Tumpey TM, Kelly GD, Hu-Primmer J, Katz JM (2001) Immunity to influenza A H9N2 viruses induced by infection and vaccination. J Virol 75:4896-4901
135. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fujii G (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24:5158-5168
136. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21:4430-4436
137. Chen H, Subbarao K, Swayne D, Chen Q, Lu X, Katz J, Cox N, Matsuoka Y (2003) Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 21:1974-1979
138. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P et al (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77-80
139. Cheung CL, Vijaykrishna D, Smith GJ, Fan XH, Zhang JX, Bahl J, Duan L, Huang K, Tai H, Wang J et al (2007) Establishment of influenza A virus (H6N1) in minor poultry species in southern China. J Virol 81:10402-10412
140. Chin PS, Hoffmann E, Webby R, Webster RG, Guan Y, Peiris M, Shortridge KF (2002) Molecular evolution of H6 influenza viruses from poultry in Southeastern China: prevalence of H6N1 influenza viruses possessing seven A/Hong Kong/156/97 (H5N1)-like genes in poultry. J Virol 76:507-516
141. Myers KP, Setterquist SF, Capuano AW, Gray GC (2007) Infection due to 3 avian influenza subtypes in United States veterinarians. Clin Infect Dis 45:4-9
142. Shortridge KF (1982) Avian influenza A viruses of southern China and Hong Kong: ecological aspects and implications for man. Bull World Health Organ 60:129-135
143. Shortridge KF (1992) Pandemic influenza: a zoonosis? Semin Respir Infect 7:11-25
144. Hoffmann E, Stech J, Leneva I, Krauss S, Scholtissek C, Chin PS, Peiris M, Shortridge KF, Webster RG (2000) Characterization of the influenza A virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1? J Virol 74:6309-6315
145. Gillim-Ross L, Santos C, Chen Z, Aspelund A, Yang CF, Ye D, Jin H, Kemble G, Subbarao K (2008) Avian influenza H6 viruses productively infect and cause illness in mice and ferrets. J Virol 82:10854-10863
146. Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G, Subbarao K (2009) Evaluation of live attenuated influenza a virus H6 vaccines in mice and ferrets. J Virol 83:65-72
147. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM (2002) Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76:4420-4429
148. Katz JM, Lu X, Frace AM, Morken T, Zaki SR, Tumpey TM (2000) Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 54:178-187
149. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT et al (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79:2191-2198
150. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194:1040-1043
151. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McCain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI et al (2004) Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363:1099-1103
152. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RAM, Osterhaus ADME, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399
153. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Influenza virus receptors in the human airway. Nature 440:435-436
154. Nicholls JM, Chan MCW, Chan WY, Wong HK, Cheung CY, Kwong DLW, Wong MP, Chui WH, Poon LLM, Tsao SW et al (2007) Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 13:147-149
155. Hinshaw VS, Webster RG, Easterday BC, Bean WJ (1981) Replication of avian influenza A viruses in mammals. Infect Immun 34:354-361
156. Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM et al (2007) A two-amino acid change in the hemagglutinin of the 1918 Influenza virus abolishes transmission. Science 315:655-659
157. Paniker CKJ, Nair CMG (1970) Infection with A2 Hong Kong influenza virus in domestic cats. Bull Wld Hlth Org 43:859-862
158. Paniker CKJ, Nair CMG (1972) Experimental infection of animals with influenza-virus types A and B. Bull Wld Hlth Org 47:461-463
159. Rimmelzwaan GF, van Riel D, Baars M, Bestebroer TM, van Amerongen G, Fouchier RA, Osterhaus AD, Kuiken T (2006) Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 168:176-183
160. Karaca K, Swayne DE, Grosenbaugh D, Bublot M, Robles A, Spackman E, Nordgren R (2005) Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 12:1340-1342
161. Saito T, Lim W, Suzuki T, Suzuki Y, Kida H, Nishimura SI, Tashiro M (2002) Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 20:125-133
162. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD (2001) Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75:6687-6691
163. Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD (2003) Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 40:304-310
164. Chen H, Li Y, Li Z, Shi J, Shinya K, Deng G, Qi Q, Tian G, Fan S, Zhao H et al (2006) Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol 80:5976-5983
165. Rudenko L (2008) Live attenuated vaccine in Russia: advantages, further research and development. In: Katz JM (ed) Options for the control of influenza VI. International Medical Press Ltd, London, Atlanta, pp 122-124
166. Rudenko L, Desheva J, Korovkin S, Mironov A, Rekstin A, Grigorieva E, Donina S, Gambaryan A, Katlinsky A (2008) Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respi Viruses 2:203-209
167. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Hyun Kim J, Halfmann P, Hatta M et al (2007) Aberrant innate immune response in lethal infection of macaques wtih the 1918 influenza virus. Nature 445:319-323
168. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K et al (2009) Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27:4953-4960
169. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR et al (2009) A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 27:3744-3753
170. Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G et al (2009) A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 199:711-716
171. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T et al (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025
172. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH et al (2009) Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487
173. Dormitzer PR, Rappuoli R, Casini D, O'Hagan D, et al (2009)Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Currents Influenza. http://knol.google.com/k/philip-r-dormitzer/adjuvant-is-necessary-for-a-robust/uhahw99c63lg/1?collectionId1/428qm4w0q65e4w.1&position1/413#. Accessed 9 Oct 2009
174. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I (2009) Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report. N Engl J Med 361:2424-2435
175. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, et al (2009) Response to a monovalent 2009 influenza A vaccine. N Engl J Med 361: 2405-2413
176. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, van de Vijver D, Boucher CA, Koopmans M, Rimmelzwaan GF et al (2009) Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481-483
177. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360:2605-2615
178. Center for Biologics Evaluation and Research (2007) Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Food and Drug Administration, Rockville, MD, USA
179. European Agency for the Evaluation of Medicinal Products (EMEA) (2004) Guideline ondossier structure and content for pandemic influenza vaccine marketing authorization application. European Agency for the Evaluation of Medicinal Products, London
180. Federal Register 21 CFR Parts 314 & 610 (2002) New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. USA
181. Loosli CG (1948) The pathogenesis and pathology of experimental air-borne influenza virus A infections in mice. J Infect Dis 84:153-168
182. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL (2000) Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81:2689-2696
183. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G (2005) Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759
184. Smith H, Sweet C (1988) Lessons from human influenza from pathogenicity studies with ferrets. Rev Infect Dis 10:56-75
185. Smith W, Stuart-Harris CH (1936) Influenza infection of man from the ferret. Lancet 228:121-123